Biologic effective in polymyalgia rheumatica

Tocilizumab monotherapy is effective in reducing the symptoms of recent-onset polymyalgia rheumatica, according to a French pilot trial.

The prospective study involved 20 patients with symptom onset within the previous 12 months who were not on glucocorticoids.

Treatment consisted of tocilizumab infusions at monthly intervals for three months, followed by low-dose prednisone.